United Orthopedic (4129) reported revenue of NT$555.6 million for Oct 2026, +7.7% year on year and +17.7% from the previous month. Revenue for Jan–Oct 2026 was NT$5.14 billion (+10.4% year on year).
In Oct 2026, it ranked No. 15 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$555.6 million | +7.7% | +17.7% |
| Sep 2026 | NT$472.2 million | -7.2% | -3.0% |
| Aug 2026 | NT$486.8 million | +7.5% | -14.2% |
| Jul 2026 | NT$567.5 million | +7.1% | +7.0% |
| Jun 2026 | NT$530.2 million | +17.1% | +5.9% |
| May 2026 | NT$500.6 million | +19.5% | -6.3% |
| Apr 2026 | NT$534.3 million | +11.5% | -6.7% |
| Mar 2026 | NT$572.6 million | +18.1% | +28.3% |
| Feb 2026 | NT$446.3 million | +7.2% | -6.1% |
| Jan 2026 | NT$475.5 million | +20.1% | -4.9% |
| Dec 2025 | NT$500.1 million | +20.5% | +0.0% |
| Nov 2025 | NT$500 million | +13.5% | -3.1% |
| Oct 2025 | NT$515.8 million | +12.1% | +1.4% |
| Sep 2025 | NT$508.9 million | +30.2% | +12.4% |
| Aug 2025 | NT$452.9 million | +40.1% | -14.5% |
| Jul 2025 | NT$529.8 million | +27.2% | +17.0% |
| Jun 2025 | NT$452.9 million | +22.6% | +8.1% |
| May 2025 | NT$418.7 million | +6.3% | -12.6% |
| Apr 2025 | NT$479.1 million | +27.0% | -1.2% |
| Mar 2025 | NT$484.9 million | +22.0% | +16.5% |
| Feb 2025 | NT$416.3 million | +40.4% | +5.1% |
| Jan 2025 | NT$396 million | +6.5% | -4.6% |
| Dec 2024 | NT$415 million | +19.8% | -5.8% |
| Nov 2024 | NT$440.6 million | +15.7% | -4.3% |
| Oct 2024 | NT$460.3 million | +13.1% | +17.8% |
Jan–Oct 2026 cumulative: NT$5.14 billion (+10.4% YoY)
Other Biotech & Medical companies
Compare with peers: United Orthopedic vs PEC / United Orthopedic vs Lotus Pharm / United Orthopedic vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16